• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • Pfizer, Astellas Amend Research Protocols for Two Enzalutamide Trials americanpharmaceuticalreview
    August 24, 2018
    Pfizer and Astellas announced amendments to the protocols for two registrational Phase 3 trials, ARCHES and EMBARK, designed to evaluate the safety and efficacy of Xtandi (enzalutamide) in men with hormone-sensitive prostate cancer (HSPC).

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service